{
  "id": "mhgap#risk_safety_ad2cfd2d",
  "content": "systematic review and network meta-analysis.\n202. Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Lancet Psychiatry. 2021;8(11):969–80 (https://doi.\nNomura I et al. Pharmacological treatment for org/10.1016/S2215-0366(21)00243-1).\nbipolar mania: a systematic review and network\n211. Oud M, Mayo-Wilson E, Braidwood R, Schulte\nmeta-analysis of double-blind randomized\nP, Jones SH, Morriss R et al. Psychological\ncontrolled trials. Mol Psychiatry. 2022;27(2):1136–\ninterventions for adults with bipolar disorder:\n44 (https://doi.org/10.1038/s41380-021-01334-4).\nsystematic review and meta-analysis. Br J\n203. Farkas R, Feeney J. Clinical review, adverse events: Psychiatry. 2016;208(3):213–22 (https://doi.\ncarbamazepine. East Hanover (NJ): Novartis org/10.1192/bjp.bp.114.157123).\nPharmaceuticals; 2007 (https://www.accessdata.\n212. Stallman HM, Allen A. Acute suicide prevention:\nfda.gov/drugsatfda_docs/nda/2007/016608s098,0\na systematic review of the evidence and\n20712s029,021710_ClinRev.pdf).\nimplications for clinical practice. J Affect Disord\n204. Meador KJ. Effects of in utero antiepileptic drug Rep. 2021;5:100148 (https://doi.org/10.1016/j.\nexposure. Epilepsy Curr. 2008;8(6):143–7 (https:// jadr.2021.100148).\ndoi.org/10.1111/j.1535-7511.2008.00273.x).\n213. Nuij C, Van Ballegooijen W, De Beurs D, Juniar\n205. Jochim J, Rifkin-Zybutz RP, Geddes J, Cipriani A. D, Erlangsen A, Portzky G et al. Safety planning-\nValproate for acute mania. Cochrane Database type interventions for suicide prevention: meta-\nSyst Rev. 2019;(10):CD004052. analysis. Br J Psychiatry. 2021;219(2):419–26\n(https://doi.org/10.1192/bjp.2021.50).\n206. Prescribing information: SOLTAMOX®",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "work",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety systematic review and network meta-analysis.\n202. Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Lancet Psychiatry. 2021;8(11):969–80 (https://doi.\nNomura I et al. Pharmacological treatment for org/10.1016/S2215-0366(21)00243-1).\nbipolar mania: a systematic review and network\n211. Oud M, Mayo-Wilson E, Braidwood R, Schulte\nmeta-analysis of double-blind randomized\nP, Jones SH, Morriss R et al. Psychological\ncontrolled trials. Mol Psychiatry. 2022;27(2):1136–\ninterventions for adults with bipolar disorder:\n44 (https://doi.org/10.1038/s41380-021-01334-4).\nsystematic review and meta-analysis. Br J\n203. Farkas R, Feeney J. Clinical review, adverse events: Psychiatry. 2016;208(3):213–22 (https://doi.\ncarbamazepine. East Hanover (NJ): Novartis org/10.1192/bjp.bp.114.157123).\nPharmaceuticals; 2007 (https://www.accessdata.\n212. Stallman HM, Allen A. Acute suicide prevention:\nfda.gov/drugsatfda_docs/nda/2007/016608s098,0\na systematic review of the evidence and\n20712s029,021710_ClinRev.pdf).\nimplications for clinical practice. J Affect Disord\n204. Meador KJ. Effects of in utero antiepileptic drug Rep. 2021;5:100148 (https://doi.org/10.1016/j.\nexposure. Epilepsy Curr. 2008;8(6):143–7 (https:// jadr.2021.100148).\ndoi.org/10.1111/j.1535-7511.2008.00273.x).\n213. Nuij C, Van Ballegooijen W, De Beurs D, Juniar\n205. Jochim J, Rifkin-Zybutz RP, Geddes J, Cipriani A. D, Erlangsen A, Portzky G et al. Safety planning-\nValproate for acute mania. Cochrane Database type interventions for suicide prevention: meta-\nSyst Rev. 2019;(10):CD004052. analysis. Br J Psychiatry. 2021;219(2):419–26\n(https://doi.org/10.1192/bjp.2021.50).\n206. Prescribing information: SOLTAMOX® Systematic review and network meta-analysis. 202."
}